T
Thomas Lehmann
Researcher at University Hospital of Basel
Publications - 33
Citations - 1676
Thomas Lehmann is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Myeloproliferative neoplasm & Polycythemia vera. The author has an hindex of 11, co-authored 33 publications receiving 1476 citations. Previous affiliations of Thomas Lehmann include University of Basel.
Papers
More filters
Journal ArticleDOI
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg,Axel Karow,Ronny Nienhold,Renate Looser,Hui Hao-Shen,Ina Nissen,Sabine Girsberger,Thomas Lehmann,Jakob Passweg,Martin Stern,Christian Beisel,Robert Kralovics,Robert Kralovics,Radek C. Skoda +13 more
TL;DR: Surprisingly, the number of mutations between early and late patient samples did not significantly change, and during a total follow-up of 133 patient years, only 2 new mutations appeared, suggesting that the mutation rate in MPN is rather low.
Journal ArticleDOI
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel,Amylou C. Dueck,Holly L. Geyer,Jean-Jacques Kiladjian,Stefanie Slot,Sonja Zweegman,Peter A. W. te Boekhorst,Suzan Commandeur,Harry C. Schouten,Federico Sackmann,Ana Kerguelen Fuentes,Dolores Hernández-Maraver,Heike L. Pahl,Martin Griesshammer,Frank Stegelmann,Konstanze Doehner,Thomas Lehmann,Karin Bonatz,Andreas Reiter,Françoise Boyer,Gabriel Etienne,Jean Christophe Ianotto,Dana Ranta,Lydia Roy,Jean-Yves Cahn,Claire N. Harrison,Deepti Radia,Pablo J. Muxi,Norman Maldonado,Carlos Besses,Francisco Cervantes,Peter L. Johansson,Tiziano Barbui,Giovanni Barosi,Alessandro M. Vannucchi,Francesco Passamonti,Bjorn Andreasson,Maria L Ferarri,Alessandro Rambaldi,Jan Samuelsson,Gunnar Birgegård,Ayalew Tefferi,Ruben A. Mesa +42 more
TL;DR: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptoms study to date.
Journal ArticleDOI
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti,Chiara Elena,Susanne Schnittger,Radek C. Skoda,Anthony R. Green,François Girodon,Jean-Jacques Kiladjian,Mary Frances McMullin,Marco Ruggeri,Carles Besses,Alessandro M. Vannucchi,Eric Lippert,Heinz Gisslinger,Elisa Rumi,Thomas Lehmann,Christina A. Ortmann,Daniela Pietra,Cristiana Pascutto,Torsten Haferlach,Mario Cazzola +19 more
TL;DR: Findings suggest that, despite the phenotypical difference, the outcome of JAK2 exon 12 mutations-positive PV is similar to that ofJAK2 (V617F)-positive PV.
Journal ArticleDOI
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Franz X. Schaub,Renate Looser,Sai Li,Hui Hao-Shen,Thomas Lehmann,André Tichelli,Radek C. Skoda +6 more
TL;DR: In 4 of 8 myeloproliferative neoplasm patients, it was found that some colonies with mutated TET2 carried wild-type JAK2, whereas others wereJAK2-V617F positive, indicating that TET1 occurred before JAK1-V615F, and the lack of a strict temporal order of occurrence makes it unlikely that mutations in TET3 represent a predisposing event for acquiring mutations in JAK3.
Journal ArticleDOI
Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation.
Nina Khanna,Ingrid Steffen,Jan Dirk Studt,A. Schreiber,Thomas Lehmann,Maja Weisser,Ursula Flückiger,Alois Gratwohl,Jörg Halter,Hans H. Hirsch,Hans H. Hirsch +10 more
TL;DR: This data indicates that hematopoietic stem cell transplantation patients after HSCs are at high risk of developing influenza, and the diagnostic methods and antiviral treatment for this disease have scarcely been investigated.